TY - JOUR
T1 - Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab
AU - Parodi, Maurizio Battaglia
AU - Iacono, Pierluigi
AU - Zucchiatti, Ilaria
AU - Bandello, Francesco
PY - 2016/11/30
Y1 - 2016/11/30
N2 - Purpose: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). Methods: This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen. Results: Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months. Conclusions: Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.
AB - Purpose: To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS). Methods: This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen. Results: Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months. Conclusions: Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.
KW - Choroidal neovascularization
KW - multiple evanescent white dot syndrome
KW - ranibizumab
UR - http://www.scopus.com/inward/record.url?scp=84997766143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84997766143&partnerID=8YFLogxK
U2 - 10.1080/09273948.2016.1247175
DO - 10.1080/09273948.2016.1247175
M3 - Article
AN - SCOPUS:84997766143
SP - 1
EP - 4
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
SN - 0927-3948
ER -